

# Effects of probiotics on the prevention of atopic dermatitis

Nam Yeun Kim, MS, Geun Eog Ji, PhD

Department of Food and Nutrition, Research Institute of Human Ecology, Seoul National University College of Human Ecology, Seoul, Korea

Received: 13 February 2012, Accepted: 27 February 2012  
Corresponding author: Geun Eog Ji, PhD  
Department of Food and Nutrition, Seoul National University College of Human Ecology, 1, Gwanak-ro, Gwanak-gu, Seoul 152-742, Korea  
Tel: +82-2-880-8749, Fax: +82-2-884-0305  
E-mail: geji@snu.ac.kr

Copyright © 2012 by The Korean Pediatric Society

Atopic dermatitis (AD) is an immune disorder that is becoming increasingly prevalent throughout the world. The exact etiology of AD remains unknown, and a cure for AD is not currently available. The hypothesis that appropriate early microbial stimulation contributes to the establishment of a balanced immune system in terms of T helper type Th1, Th2, and regulatory T cell (Treg) responses has led to the use of probiotics for the prevention and treatment of AD in light of various human clinical studies and animal experiments. Meta-analysis data suggests that probiotics can alleviate the symptoms of AD in infants. The effects of balancing Th1/Th2 immunity and enhancing Treg activity via the interaction of probiotics with dendritic cells have been described *in vitro* and in animal models, although such an effect has not been demonstrated in human studies. In this review, we present some highlights of the immunomodulatory effects of probiotics in humans and animal studies with regard to their effects on the prevention of AD.

**Key words:** Probiotics, Dermatitis, Atopic, Prevention, Immunomodulation, Immune system

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Introduction

Atopic dermatitis (AD) is a common, chronic, and refractory skin disease manifesting as eczema and pruritus with repeated exacerbations and regressions<sup>1</sup>. The prevalence of allergic diseases such as AD, asthma, and allergic rhinitis (AR) has increased throughout the world during the last 30 years, with the cumulative prevalence of AD in children reaching 8 to 20%<sup>2</sup>, although the eczema symptom prevalence for children 13 to 14 years of age has decreased in some previously high-prevalence areas in the developed world, such as the United Kingdom and New Zealand<sup>3</sup>. The prevalence of allergy tends to be lower in a family with a higher number of siblings; the incidence of allergic diseases increases when one moves from a low-

prevalence area to a high-prevalence area and is higher in urban areas than in rural areas. These observations emphasize the importance of environmental factors in the development of allergic diseases, as well the role of genetic factors and the maturity of epithelial cell barrier functions<sup>4</sup>. A systematic review found no strong evidence of a protective effect of exclusive breastfeeding for at least 3 months against eczema, even in those with a positive family history of atopy<sup>5</sup>. Environmental factors that may contribute to the increased development of AD include decreased microbial exposure due to urbanization, the use of vaccines and antibiotics, and improved infant sanitation. Exposure of infants to farm animals, pets, and daycare environments is known to be helpful for the introduction of benign challenges, including various non-pathogenic microorganisms,

which leads to the establishment of protective immunity against allergic disorders<sup>4</sup>). The intestinal immune system comprises the largest portion of the overall immune system and remains exposed to intestinal bacteria, thus accounting for the largest source of microbial exposure in humans. The immune system of neonatal infants is not fully developed and is prone to an immature T helper type Th2-dominant state. Infants undergo environment-driven maturation to establish a balance between Th1, Th2, Th17, and regulatory T cell (Treg) responses; appropriate microbial stimulation in early life contributes to the establishment of a balanced immune system<sup>6</sup>). In AD, the onset of acute skin lesions is initiated by Th2-dominant cells. If this initial Th2 cellular response is not suppressed, a subsequent Th1 response is induced, consisting of inflammatory reactions resulting in chronic inflammation due to the secretion of pro-inflammatory cytokines by dying keratinocytes<sup>7</sup>.

### The effect of probiotics in human studies

Probiotics administered in sufficient amounts can have a beneficial effect on the health of the host<sup>8</sup>). Probiotics can relieve travelers' diarrhea, antibiotic-associated diarrhea, atopic eczema, and irritable bowel syndrome (IBS)<sup>9</sup>). Infants with AD or other allergic diseases show less frequent intestinal colonization with probiotics such as

*Lactobacillus* or *Bifidobacterium* and more frequent colonization with *Clostridium* relative to non-allergic infants<sup>10</sup>). Recently, the administration of probiotic bacteria was reported to help maintain anti-inflammatory and tolerant immunity, which resulted in a lower prevalence of allergy in human subjects (Table 1). Potential mechanisms explaining the health-promoting actions of probiotic bacteria may include modulation of the intestinal immune system and displacement of potential pathogens via competitive exclusion or the production of antimicrobial agents. The efficacy of probiotics in the prevention of AD was primarily observed in infants who were administered probiotics during the perinatal period. Hattori et al.<sup>31</sup>) reported that children with AD and with a low degree of intestinal *Bifidobacterium* colonization experienced an amelioration of their allergic symptoms when lyophilized *Bifidobacterium* was administered orally. Systematic analysis in some clinical studies suggested that the intake of probiotics by mothers during pregnancy reduces the incidence of subsequent eczema<sup>5</sup>). Young children with immunoglobulin E (IgE)-mediated atopic eczema, in particular, showed more significant improvement with the administration of probiotics<sup>32</sup>). Other studies have also shown that the adult immune system is more difficult to modulate by the administration of probiotics. An analysis of systematic reviews suggests that there is little evidence to support a clinically useful benefit of using probiotics

**Table 1.** The Effects of Probiotics on Allergic Diseases in Human Clinical Trials (since 2009)

Year	Group	Strains (formula)	Definition of subjects completed the trial	Intervention method	Dose	Time of treatment	Outcome
2012	Gore, et al. <sup>11</sup>	<i>L. paracasei</i> CNCM I-2116 or <i>B. lactis</i> CNCM I-3446	137 Infants with eczema at age 3-6 months	Placebo-control trials	10 <sup>10</sup> CFUs of either lyophilized powdered CNCM I-2116 or CNCM I-3446 daily	12 Weeks	No effect on treatment and secondary prevention effects
2011	Roessler, et al. <sup>12</sup>	A probiotic mixture ( <i>L. paracasei</i> Lpc-37, <i>L. acidophilus</i> 74-2, <i>B. animalis</i> subsp. <i>lactis</i> DGCC 420)	15 Healthy adults, 15 patients with AD	A randomized, placebo-controlled study	2x100 mL/day of either a probiotic or a placebo drink	8 Weeks	Reduction of genotoxic activity of faecal water in patients with AD
2011	Larsen, et al. <sup>13</sup>	<i>L. acidophilus</i> NCFM, <i>B. lactis</i> Bi-07	50 Young children with AD	RDC	10 <sup>10</sup> CFU daily	8 Weeks	No affect on the composition and diversity of the main bacterial populations in feces
2011	Morisset, et al. <sup>14</sup>	A non-hydrolyzed, fermented milk formula containing heat-killed <i>B. breve</i> C50, <i>S. thermophilus</i> 065 (HKBBST milk)	After birth until 2-year-old, 124 children at high risk of atopy	RDC	<i>B. breve</i> C50 (4.2x10 <sup>9</sup> bacteria per 100 g of powder formula), <i>S. thermophilus</i> 065 (3.84x10 <sup>7</sup> bacteria per 100 g of powder formula) daily	12 Months	Reduction of digestive and respiratory events
2011	Torii, et al. <sup>15</sup>	<i>L. acidophilus</i> L-92 (L-92)	Japanese children with AD	A double-blind, placebo-controlled study	-	Long-term administration	Shown a complementary effect on the standard medical therapy in patients with AD through the alteration in the Th1/Th2
2011	Boyle, et al. <sup>16</sup>	<i>L. rhamnosus</i> GG (LGG)	250 Pregnant women carrying infants at high risk of allergic disease	RCT	LGG (1.8x10 <sup>10</sup> CFUs) daily	From 36 weeks gestation until delivery	Not sufficient for preventing eczema

**Table 1.** The Effects of Probiotics on Allergic Diseases in Human Clinical Trials (since 2009) (Continued)

Year	Group	Strains (formula)	Definition of subjects completed the trial	Intervention method	Dose	Time of treatment	Outcome
2011	Kukkonen, et al. <sup>17)</sup>	<i>L. rhamnosus</i> GG (ATCC53103), <i>L. rhamnosus</i> LC705 (DSM7061), <i>B. breve</i> Bb99 (DSM13692), <i>P. freudenreichii</i> ssp. <i>shermanii</i> JS (DSM7076)	1,018 Mothers with high risk and their 688 infants at age 2	RDC	<i>L. rhamnosus</i> GG ( $5 \times 10^9$ CFUs), <i>L. rhamnosus</i> LC705 ( $5 \times 10^9$ CFUs), <i>B. breve</i> Bb99 ( $2 \times 10^9$ CFUs), <i>P. freudenreichii</i> ssp. <i>shermanii</i> JS ( $2 \times 10^9$ CFUs), twice daily	From 36 weeks gestation after delivery 6 months	No immunomodulatory effect
2011	Nermes, et al. <sup>18)</sup>	<i>L. rhamnosus</i> GG (LGG)	39 Infants with AD	A double-blind design	LGG ( $3.4 \times 10^9$ CFUs) daily	3 Months	Improvement of gut barrier function
2011	van der Aa, et al. <sup>19)</sup>	A formula with <i>B. breve</i> M-16V, a galacto/fructooligosaccharide mixture (immunofortis)	75 Infants with AD, age < 7 months	RDC, multicentre trial	-	12 Weeks	Preventive effect on the asthma-like symptoms in infants with AD
2011	Moroi, et al. <sup>20)</sup>	Supplementary diet containing heat-killed lactic acid bacterium <i>L. paracasei</i> K71	34 Adult patients with AD	RDC	-	>12 Weeks	Beneficial effect on adult type AD
2010	Hoang, et al. <sup>21)</sup>	<i>L. rhamnosus</i> cell lysate	14 Patients (age 8-64 months) with a history resistant eczema for a period of at least 6 months	Open label non-randomized clinical observation	300-500 mg standardized <i>L. rhamnosus</i> cell lysate daily	-	Effective on the treatment and prevention of childhood eczema
2010	Dotterud, et al. <sup>22)</sup>	Probiotic milk containing <i>L. rhamnosus</i> GG, <i>L. acidophilus</i> La-5, <i>B. animalis</i> subsp. <i>lactis</i> Bb-12 (Biola)	Children from a non selected maternal, women from 36 weeks of gestation to 3 months postnatally during breastfeeding (pregnant women=415) (children =278)	Randomized, double-blind trial	250 mL probiotic low fat fermented milk ( $5 \times 10^9$ CFUs each bacterium) daily	From 36 weeks of gestation until 3 months postnatally	No effect on atopic sensitization
2010	Chen, et al. <sup>23)</sup>	<i>L. gasseri</i> A5	$10^5$ Asthmatic children with AR (6-12 years)	RDC	One capsule ( $2 \times 10^9$ CFUs)	8 Weeks	Clinical benefits through the clinical symptom and immunological parameters including cytokine production
2010	Gerasimov, et al. <sup>24)</sup>	<i>L. acidophilus</i> DDS-1, <i>B. lactis</i> UABLA-12 with fructooligosaccharide	90 Children aged 1-3 years with moderate-to-severe AD	RDC	5 Billion CFUs twice daily	8 Weeks	Clinical improvement with corresponding lymphocyte subset changes in peripheral blood
2010	Rose, et al. <sup>25)</sup>	<i>L. rhamnosus</i> GG	131 Children (6-24 months old) at high risk of allergic sensitization, asthma	Double-blind dietary supplement	$10^{10}$ CFUs twice daily	>6 Months	No clinical effect
2010	Kim, et al. <sup>26)</sup>	A probiotic mixture ( <i>B. bifidum</i> BGN4, <i>B. lactis</i> AD011, <i>L. acidophilus</i> AD031)	112 Pregnant women with a family history of allergic diseases and their infants	RDC	BGN4 ( $1.6 \times 10^9$ CFUs), AD011 ( $1.6 \times 10^9$ CFUs), AD031 ( $1.6 \times 10^9$ CFUs) once daily	8 Weeks before the expected delivery to 3 months after delivery following breast-feeding until 3 months of age and formula-feeding of a probiotic mixture until 6 months of age	Effective on the primary prevention of eczema
2010	Woo, et al. <sup>27)</sup>	<i>L. sakei</i> KCTC10755BP	75 Children aged 2-10 years with AEDS	RDC	Daily	12 Weeks	A substantial clinical improvement

**Table 1.** The Effects of Probiotics on Allergic Diseases in Human Clinical Trials (since 2009) (Continued)

Year	Group	Strains (formula)	Definition of subjects completed the trial	Intervention method	Dose	Time of treatment	Outcome
2009	Niers, et al. <sup>28)</sup>	A probiotic mixture ( <i>B. bifidum</i> , <i>B. lactis</i> , <i>Lactococcus lactis</i> ; Ecologic Panda)	Pregnant women with a family history of allergic diseases and their infants	RDC	3×10 <sup>9</sup> CFUs (1×10 <sup>9</sup> CFUs of each strain) once daily	6 Weeks before the expected delivery to 12 months after delivery	Preventive effect on the incidence of eczema in high-risk children and maintenance during the first 2 years of life
2009	Soh, et al. <sup>29)</sup>	<i>B. longum</i> (BL999), <i>L. rhamnosus</i> (LPR)	Asian infants at risk of allergic disease	RDC	BL999 (1×10 <sup>7</sup> CFUs/g), LPR (2×10 <sup>7</sup> CFUs/g) daily	For the first 6 months	No effect on prevention of eczema or allergen sensitization
2009	Kuitunen, et al. <sup>30)</sup>	A probiotic mixture (2 lactobacilli, bifidobacteria, propionibacteria)	1,223 Mothers with infants at high risk for allergy	A double-blinded, placebo-controlled study	A capsule of LGG (5×10 <sup>9</sup> CFUs), <i>L. rhamnosus</i> (5×10 <sup>9</sup> CFUs), <i>B. breve</i> (2×10 <sup>8</sup> CFUs), <i>P. freudenreichii</i> ssp. <i>shermanii</i> JS (2×10 <sup>9</sup> CFUs) twice daily	During the last month of pregnancy and their infants to receive a probiotic mixture from birth until age 6 months	No allergy-preventive effect except in cesarean-delivered children

*L.*, *Lactobacillus*; *B.*, *Bifidobacterium*; *S.*, *Streptococcus*; *P.*, *Propionibacterium*; CFU, colony-forming unit; AD, atopic dermatitis; AR, allergic rhinitis; AEDS, atopic eczema-dermatitis syndrome; RDC, a randomized, double-blind, placebo-controlled study; RCT, a randomized, placebo-controlled trials.

in patients with established eczema, although immunomodulation may also occur in adulthood<sup>5)</sup>. No beneficial effect was found from *B. lactis* or *L. paracasei* supplementation in the treatment of eczema when given as an adjunct to basic topical treatment, and no effect on the progression of allergic disease from age 1 to 3 years was noted<sup>11)</sup>. The preventive effect of probiotics is strain specific; when *L. rhamnosus* HN001 and *B. animalis* subsp. *lactis* HN019 were compared, only *L. rhamnosus* HN001 reduced (by 2 years) the cumulative prevalence of eczema in infants at risk of allergic disease<sup>33)</sup>. In various studies, the tested probiotic mixtures contained different strains, and individual strains were not tested. Therefore, it is still premature to conclude that individual component strain can have a synergistic effect when combined into a mixture, as comparisons of the effect of a probiotic mixture with that of one or more of its component strains have not been performed, particularly for severe diseases. Early life administration of a cow's milk formula supplemented with *B. longum* BL999 and *L. rhamnosus* LPR showed no effect on the prevention of eczema or allergen sensitization in the first year of life in infants at risk for allergic disease<sup>29)</sup>.

Occasionally, an identical strain shows contradictory results. In the case of *L. rhamnosus* GG, early reports suggested that *L. rhamnosus* GG (1×10<sup>10</sup> colony-forming units [CFUs] of *L. rhamnosus* GG daily) administered to pregnant mothers and subsequently to infants after delivery reduced the incidence of AD by half relative to those treated with placebo<sup>34)</sup>. However, a more recent study that employed a nearly identical study design showed that supplementation of *L. rhamnosus* GG (5×10<sup>9</sup> CFUs twice daily during pregnancy and early infancy) did not reduce the incidence and the severity of AD in affected children. Rather, probiotic supplementation was associated

with an increased rate of recurrent episodes of wheezing bronchitis<sup>35)</sup>. Moreover, oral administration of *L. rhamnosus* GG in a prospective, double-blind, randomized, placebo-controlled study had no clinical effect on AD or asthma-related events in young children (6 to 24 months old) with recurrent wheezing and a family history of atopy<sup>25)</sup>.

Although a meta-analysis revealed the positive potential of probiotics, the mechanism of action or biomarkers related to their anti-AD effect were not clarified. The reduction of AD prevalence in infants with a family history of allergic diseases by the administration of a probiotic mixture (*B. bifidum* BGN4, *B. lactis* AD011, and *L. acidophilus* AD031) was associated with significant increases in the capacity of transforming growth factor beta (TGF-β) production by peripheral blood mononuclear cells<sup>36)</sup>. When 62 mother and infant pairs were supplemented with probiotics during pregnancy and their breastfeeding period, the level of TGF-β<sub>2</sub> was higher in the breast milk from mothers in the probiotics group than in that from mothers in the control group<sup>37)</sup>. Compared with a placebo, the administration of *L. sakei* KCTC 10755BP to children aged 2 to 10 years with atopic eczema-dermatitis syndrome and a minimum SCORing of Atopic Dermatitis (SCORAD) score of 25 resulted in a decreased SCORAD total score associated with lower pretreatment-adjusted serum levels of chemokine (c-c motif) ligand CCL17 and CCL27, which are chemokines involved in the process of establishing inflammatory infiltration of cells<sup>27)</sup>. Oral administration of combined *L. rhamnosus* and *L. reuteri* improved the extent of the eczema and decreased serum eosinophil cationic protein levels in children<sup>38)</sup>; this effect was more pronounced in patients with a positive skin prick test response and elevated IgE levels. Supplementation of *B. lactis* Bb-12 or *L. rhamnosus* GG to infants with atopic eczema during the weaning

period reduced the extent and the severity of atopic eczema, which was accompanied by the reduction of serum cluster of differentiation (CD)4 and urine eosinophilic protein X<sup>39</sup>. Taken together, the results from the 3 clinical studies described above suggest that probiotics improve the symptoms of inflammatory responses in allergic diseases beyond the intestinal milieu<sup>39</sup>. An increase in the traffic of circulating CD34+ hematopoietic precursor cells (HPCs) was suggested to be a factor in systemic allergic inflammation<sup>40</sup>. In 14 allergic patients who were 6 to 48 years old with clinical symptoms of asthma and/or conjunctivitis, rhinitis, urticaria, AD, food allergy, and IBS, the number of circulating CD34+ HPC was decreased when a mixture of *L. acidophilus*, *L. delbrueckii*, and *Streptococcus thermophilus* was administered for 30 days<sup>40</sup>. A study to assess whether the administration of probiotics affects the microbiota and its genotoxic activity in healthy subjects and patients with AD revealed that the administration of a probiotic mix containing *L. paracasei* Lpc-37, *L. acidophilus* 74-2, and *B. animalis* subsp. *lactis* DGCC 420 decreased the genotoxic potential of fecal water in AD patients. The fecal *C. perfringens* cluster I-II levels remained unaffected, suggesting either a change in their activity or that other bacterial species are responsible for the reduced genotoxic activity of fecal water<sup>12</sup>. In an allergic condition, the function of Tregs and their production of cytokines such as interleukin (IL)-10 and TGF- $\beta$  are dysregulated compared to the normal condition, resulting in prolonged inflammatory responses against environmental allergens<sup>41</sup>. The intestinal epithelial cells secrete thymic stromal lymphopoietin, TGF- $\beta$ , and retinoic acid, which induce the development of resident CD11b regulatory dendritic cells (DCs), which in turn induce the development of naive T cells into forkhead box family transcription factor Foxp3<sup>+</sup> Tregs<sup>42</sup>. One plausible reason as to why the administration of probiotics can downregulate both Th2-related allergy and Th1-related inflammatory symptoms is related to the action of probiotics to improve regulatory immune activity, as evidenced by the results of animal experiments<sup>43</sup>. Actually, low-grade inflammation was suggested as a key factor, not only in the pathogenesis of AD but also in IBS. Consistent with this, the administration of *B. bifidum* BGN4-containing probiotics improved both AD and irritable syndrome in 2 separate clinical trials, as described below. In double-blind, randomized, placebo-controlled human trials, infants who were perinatally administered a combination of *B. bifidum* BGN4, *B. lactis* AD011, and *L. acidophilus* AD031 showed significantly lower prevalence and cumulative incidence of AD than a placebo group<sup>26</sup>. In a prospective, double-blind, randomized, placebo-controlled clinical study, IBS patients that received composite probiotics (*B. bifidum* BGN4, *B. lactis* AD011, *L. acidophilus* AD031, and *L. casei* IBS041) showed significant reductions in

their IBS symptoms, including abdominal pain, after 8 weeks of treatment. This was observed particularly in the patients with mixed or diarrhea-predominant ailments<sup>44</sup>. However, an analysis of the function of the Tregs and the expression of Foxp3<sup>+</sup> does not have close clinical relevance when judging the efficacy of probiotics in AD patients, due to the various conflicting results pertaining to the relationship between the function of the regulatory cells and the occurrence of allergic symptoms. The suppressive function of the Tregs was diminished in infants with egg allergies<sup>45</sup>. Paradoxically, CD4+CD25+ Tregs expressing Foxp3<sup>+</sup> were increased in patients with AD compared to normal individuals<sup>46</sup>. Likewise, children with AD had significantly higher induced Foxp3<sup>+</sup> expression following stimulation with both house dust mites and ovalbumin (OVA) allergens compared to those without AD, which was suggested to reflect secondary compensatory mechanisms<sup>47</sup>. In addition, the administration of *L. acidophilus* LAVRI-A1 did not have significant effects on CD4+CD25+CTLA4+ cell numbers or Foxp3<sup>+</sup> expression in high-risk children<sup>47</sup>.

In addition to probiotics, prebiotics have also shown some efficacy in ameliorating AD. When the effects of *L. salivarius* and fructooligosaccharide (synbiotic) with fructooligosaccharide alone (prebiotic) were compared in children with moderate to severe AD, the synbiotic combination was superior to the prebiotic alone for treating moderate to severe childhood AD<sup>48</sup>.

Preschool children receiving synbiotics (*L. acidophilus* DDS-1, *B. lactis* UABLA-12 with fructooligosaccharide) showed a greater decrease in the mean SCORAD score and need for topical corticosteroids than children in the placebo group after 8 weeks. Interestingly, a flow cytometric analysis of lymphocyte subsets in the peripheral blood of patients in the probiotic group showed that the percentage of CD4 and the percentage and absolute count of CD25 decreased whereas the percentage and absolute count of CD8 increased<sup>24</sup>.


While most of the clinical studies used live forms of probiotic bacteria, Hoang et al.<sup>21</sup> used the cell lysate of *L. rhamnosus*, reporting a substantial improvement in the quality of life, skin symptoms, and day and night-time irritation scores in children that received supplementation; however, this study was limited in its meaningfulness due to its open label, non-randomized clinical observation. The skin severity scores of AD decreased in the adult patients from baseline values at week 8 and week 12 when the subjects were given a diet containing heat-killed *L. paracasei*. However, the effect was largely limited because there was no significant difference between the *Lactobacillus* and placebo groups<sup>20</sup>. The administration of heat-killed *Lactobacillus* or administration onto established eczema may be a factor related to its weak effect observed in the study.

An effect of probiotics on the improvement of allergic diseases other than AD has also been reported. Daily supplementation with *L. gasseri* A5 for 8 weeks improved the clinical symptoms and immunoregulatory changes in school children suffering from asthma and AR<sup>23</sup>. The prevalence of "frequent wheezing" and "wheezing and/or noisy breathing apart from colds" was significantly lower in the synbiotic (*B. breve* M-16V and a galacto/fructooligosaccharide mixture) than in the placebo group, despite the fact that the total IgE levels did not differ between the groups<sup>19</sup>.

### The efficacy and actions of probiotics in animal studies

Recently, numerous publications have supported the effect of probiotics on the prevention and treatment of allergic diseases in

animal studies. However, the suggested mechanisms related to their anti-allergic effects were variable. The action of probiotics to shift the immune system from the pathogenic Th2 response to a Th1/T regulatory response was demonstrated (Fig. 1). Oral treatment with the probiotic mixture VSL#3 was effective in redirecting allergen-specific Th2 polarized immune responses towards Th1/T regulatory responses. This treatment also offered protection against allergen-induced anaphylactic reactions in a murine model of food allergy<sup>49</sup>. The oral administration of *L. rhamnosus* GG in OVA-immunized rats induced OVA-specific hyporesponsiveness and reduced the OVA-induced proliferative response in mesenteric lymph nodes (MLNs) associated with CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cell expansion and increased IL-10 and TGF- $\beta$  secretion<sup>51</sup>. Exposure to the commensals and saprophytes in the absence of true danger signals from invasive pathogens and/or injured host cells were reported to induce the



**Fig. 1.** Schematic view of the potential mechanism of action by which commensal bacteria and pathogenic bacteria interact with Toll-like receptors (TLRs) and elicit different immune responses. (A) Commensal and probiotic bacteria interact with intestinal epithelial-cell barrier and dendritic cells (DCs) resident in the intestine. Some cytokines, including interleukin (IL)-10, transforming growth factor beta (TGF- $\beta$ ) and thymic stromal lymphopoietin (TSLP), are expressed in intestinal epithelial cells, as a result of their interactions. Stimulation of cell TLR mediated by bacteria leads to up-regulation of TGF- $\beta$  and IL-10, which in turn may limit the responsiveness of intestinal DCs resulting in the expansion and/or survival of T-cells with regulatory capacities, and limiting the ability of driving Th1, Th2 and Th17-cell responses. (B) Pathogenic bacteria have virulence factors that interact with intestinal epithelial-cell barrier and DCs resident in the intestine. Invasion of epithelium and direct interaction with DCs lead to activation of TLR and enhanced production of pro-inflammatory cytokines including interferon-gamma (IFN- $\gamma$ ) and IL-12, which are capable of driving Th1, Th2 and Th17 response. RA, retinoic acid; sIgA, secreted Ig A; Th, T helper cell; Treg, T regulatory cell (Reprinted from Gomez-Llorente C, Munoz S, Gil A. Proc Nutr Soc 2010; 69:381-9, with permission of Cambridge University Press)<sup>50</sup>.

actions of regulatory network<sup>41)</sup> such as Tregs and inducible Tregs (Th3, Tr1) as well as Foxp3<sup>+</sup>. Foxp3<sup>+</sup> is crucial for both the differentiation of Tregs and the maintenance of their suppressive function<sup>52)</sup>. The induction of bacterial strain-specific Foxp3<sup>+</sup> Tregs was evident in mice treated with *B. longum* AH1206 but not in mice treated with *L. salivarius* AH102, suggesting that the induction of Foxp3<sup>+</sup> Tregs was strain specific<sup>53)</sup>. The regulatory network including, in addition to Tregs, DCs and the cytokines produced by these cells is essential in the development of tolerance. Kwon et al.<sup>43)</sup> showed that IRT5, a probiotic mixture, exerted potent immunomodulatory effects by upregulating or enhancing the generation of Tregs by tolerogenic DCs in MLN. Moreover, the migration of CD4<sup>+</sup> Foxp3<sup>+</sup> Tregs to sites of inflammation effectively suppressed disease progression. The enhanced therapeutic efficacy was associated with an increase in anti-inflammatory cytokines (IL-10 and TGF- $\beta$ ) as well as a decrease in pro-inflammatory cytokines.

The effect of *L. casei* in inhibiting allergic inflammation by acting at the effector phase of adaptive immune responses instead of at the initiation phase was also reported<sup>54)</sup>. The suppressive effects of *L. gasseri* OLL2809 on inflammatory responses was associated with the suppression of CD4<sup>+</sup> T cell proliferation through a MyD88-dependent signaling pathway and by *L. gasseri* OLL2809 and its RNA<sup>55)</sup>.

The oral treatment of neonatal pigs with *L. lactis* significantly reduced the subsequent frequency of allergy to ovomucoid and was associated with lower IgG(1)/IgG(2) and IgE/IgG(2) ratios, indicating a Th1 bias and a reduced Th2 immune response<sup>56)</sup>. Kim et al.<sup>57)</sup> showed that *B. bifidum* BGN4 and *L. casei* appeared to be useful probiotic bacteria for the prevention of allergy, suggesting that these bacteria induce anti-allergenic processes through the induction of the Th1 response and the regulatory lymphocyte. Pochard et al.<sup>58)</sup> demonstrated that *L. plantarum*, *L. lactis*, *L. casei*, and *L. rhamnosus* GG suppressed IL-4 and IL-5 (Th2 cytokines) and increased interferon-gamma (IFN- $\gamma$ ) and IL-12 (Th1 cytokines) in a dose-dependent manner, suggesting a more balanced Th1/Th2 response *in vitro* with human polymorphonuclear cells.

The observation that probiotics enhanced the production of Th1 and regulatory cytokines *in vitro* but slightly decreased the *ex vivo* production of IL-10, tumor necrosis factor-alpha, and IL-6 suggests that the effect of probiotics with regard to the immunomodulatory potential differed depending on the *in vitro* or *ex vivo* treatment<sup>59)</sup>. Moreover, changes in the production of various cytokines and the activation of immunoregulatory cells as observed in animal studies have not been revealed in human studies.

## Conclusions

Various meta-analysis and systematic review studies have shown positive effects of probiotics with regard to the prevention of AD, particularly in infants who were administered probiotics during the perinatal period. However, further studies regarding the optimal dose, effective probiotic strains, the timing and duration of supplementation, the additive/synergistic effects between probiotics and prebiotics, and patient populations that would most benefit from the use of probiotics need to be more thoroughly investigated. While there is substantial evidence for the amelioration of AD by probiotics from *in vitro* experiments and animal studies, the results from human clinical trials are more complicated. Thus elucidating the effects and mechanisms of action of probiotics is difficult due to the variation of results derived from human studies. Therefore, the mechanism involved in the preventive effect of probiotics in humans and the long-term effects of probiotics on the developing immune system remain to be proven.

## Acknowledgment

This study was supported by the Small and Medium Business Administration (No. S1072365) and the Next-Generation BioGreen 21 Program (No. PJ008005), from the Rural Development Administration of the Republic of Korea.

## References

1. Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, et al. Guidelines for management of atopic dermatitis. *J Dermatol* 2009;36:563-77.
2. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 2006;368:733-43.
3. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR; International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? *J Allergy Clin Immunol* 2008;121:947-54.e15.
4. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. *J Allergy Clin Immunol* 1999;103(1 Pt 1):125-38.
5. Batchelor JM, Grindlay DJ, Williams HC. What's new in atopic eczema? An analysis of systematic reviews published in 2008 and 2009. *Clin Exp Dermatol* 2010;35:823-7.
6. Ji GE. Probiotics in primary prevention of atopic dermatitis. *Forum Nutr* 2009;61:117-28.
7. Akdis CA, Blaser K, Akdis M. Apoptosis in tissue inflammation and

- allergic disease. *Curr Opin Immunol* 2004;16:717-23.
8. World Health Organization, Food and Agriculture Organization of the United Nations [Internet]. Geneva: WHO/FAO; c2012 [Jan 20]. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria: report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Available from: [http://www.who.int/foodsafety/publications/fs\\_management/en/probiotics.pdf](http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf).
  9. Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? *Eur J Nutr* 2011;50:1-17.
  10. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. *J Allergy Clin Immunol* 2001;108:516-20.
  11. Gore C, Custovic A, Tannock GW, Munro K, Kerry G, Johnson K, et al. Treatment and secondary prevention effects of the probiotics *Lactobacillus paracasei* or *Bifidobacterium lactis* on early infant eczema: randomized controlled trial with follow-up until age 3 years. *Clin Exp Allergy* 2012;42:112-22.
  12. Roessler A, Forssten SD, Gleis M, Ouwehand AC, Jahreis G. The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: a randomized, placebo-controlled study. *Clin Nutr* 2012;31:22-9.
  13. Larsen N, Vogensen FK, Gobel R, Michaelsen KF, Abu Al-Soud W, Sorensen SJ, et al. Predominant genera of fecal microbiota in children with atopic dermatitis are not altered by intake of probiotic bacteria *Lactobacillus acidophilus* NCFM and *Bifidobacterium animalis* subsp. *lactis* Bi-07. *FEMS Microbiol Ecol* 2011;75:482-96.
  14. Morisset M, Aubert-Jacquelin C, Soulaïnes P, Moneret-Vautrin DA, Dupont C. A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy. *Eur J Clin Nutr* 2011;65:175-83.
  15. Torii S, Torii A, Itoh K, Urisu A, Terada A, Fujisawa T, et al. Effects of oral administration of *Lactobacillus acidophilus* L-92 on the symptoms and serum markers of atopic dermatitis in children. *Int Arch Allergy Immunol* 2011;154:236-45.
  16. Boyle RJ, Ismail IH, Kivivuori S, Licciardi PV, Robins-Browne RM, Mah LJ, et al. *Lactobacillus GG* treatment during pregnancy for the prevention of eczema: a randomized controlled trial. *Allergy* 2011;66:509-16.
  17. Kukkonen AK, Savilahti EM, Haahela T, Savilahti E, Kuitunen M. Ovalbumin-specific immunoglobulins A and G levels at age 2 years are associated with the occurrence of atopic disorders. *Clin Exp Allergy* 2011;41:1414-21.
  18. Nermes M, Kantele JM, Atosuo TJ, Salminen S, Isolauri E. Interaction of orally administered *Lactobacillus rhamnosus GG* with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. *Clin Exp Allergy* 2011;41:370-7.
  19. van der Aa LB, van Aalderen WM, Heymans HS, Henk Sillevius Smitt J, Nauta AJ, Knippels LM, et al. Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis. *Allergy* 2011;66:170-7.
  20. Moroi M, Uchi S, Nakamura K, Sato S, Shimizu N, Fujii M, et al. Beneficial effect of a diet containing heat-killed *Lactobacillus paracasei* K71 on adult type atopic dermatitis. *J Dermatol* 2011;38:131-9.
  21. Hoang BX, Shaw G, Pham P, Levine SA. *Lactobacillus rhamnosus* cell lysate in the management of resistant childhood atopic eczema. *Inflamm Allergy Drug Targets* 2010;9:192-6.
  22. Dotterud CK, Storro O, Johnsen R, Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. *Br J Dermatol* 2010;163:616-23.
  23. Chen YS, Jan RL, Lin YL, Chen HH, Wang JY. Randomized placebo-controlled trial of *Lactobacillus* on asthmatic children with allergic rhinitis. *Pediatr Pulmonol* 2010;45:1111-20.
  24. Gerasimov SV, Vasjuta VV, Myhovich OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. *Am J Clin Dermatol* 2010;11:351-61.
  25. Rose MA, Stieglitz F, Koksall A, Schubert R, Schulze J, Zielen S. Efficacy of probiotic *Lactobacillus GG* on allergic sensitization and asthma in infants at risk. *Clin Exp Allergy* 2010;40:1398-405.
  26. Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, et al. Effect of probiotic mix (*Bifidobacterium bifidum*, *Bifidobacterium lactis*, *Lactobacillus acidophilus*) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. *Pediatr Allergy Immunol* 2010;21(2 Pt 2):e386-93.
  27. Woo SI, Kim JY, Lee YJ, Kim NS, Hahn YS. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Ann Allergy Asthma Immunol* 2010;104:343-8.
  28. Niers L, Martin R, Rijkers G, Sengers F, Timmerman H, van Uden N, et al. The effects of selected probiotic strains on the development of eczema (the PandA study). *Allergy* 2009;64:1349-58.
  29. Soh SE, Aw M, Gerez I, Chong YS, Rauff M, Ng YP, et al. Probiotic supplementation in the first 6 months of life in at risk Asian infants: effects on eczema and atopic sensitization at the age of 1 year. *Clin Exp Allergy* 2009;39:571-8.
  30. Kuitunen M, Kukkonen K, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. *J Allergy Clin Immunol* 2009;123:335-41.
  31. Hattori K, Yamamoto A, Sasai M, Taniuchi S, Kojima T, Kobayashi Y, et al. Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis. *Arerugi* 2003;52:20-30.
  32. Savilahti E, Kuitunen M, Vaarala O. Pre and probiotics in the prevention and treatment of food allergy. *Curr Opin Allergy Clin Immunol* 2008;8:243-8.
  33. Wickens K, Black PN, Stanley TV, Mitchell E, Fitzharris P, Tannock GW, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol* 2008;122:788-94.
  34. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. *Lancet* 2001;357:1076-9.
  35. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of *Lactobacillus GG* supplementation. *Pediatrics* 2008;121:e850-6.
  36. Kim JY, Choi YO, Kwon JH, Ahn KM, Park MS, Ji GE. Clinical effects of probiotics are associated with increased transforming growth factor- $\beta$  responses in infants with high-risk allergy. *J Korean Soc Appl Biol Chem* 2011;54:944-8.
  37. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic



- disease in the infant. *J Allergy Clin Immunol* 2002;109:119-21.
38. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol* 2003;111:389-95.
  39. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. *Clin Exp Allergy* 2000;30:1604-10.
  40. Mastrandrea F, Coradduzza G, Serio G, Minardi A, Manelli M, Ardito S, et al. Probiotics reduce the CD34+ hemopoietic precursor cell increased traffic in allergic subjects. *Eur Ann Allergy Clin Immunol* 2004;36:118-22.
  41. von Hertzen LC, Savolainen J, Hannuksela M, Klaukka T, Lauerma A, Mäkelä MJ, et al. Scientific rationale for the Finnish Allergy Programme 2008-2018: emphasis on prevention and endorsing tolerance. *Allergy* 2009;64:678-701.
  42. Ng SC, Kamm MA, Stagg AJ, Knight SC. Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation. *Inflamm Bowel Dis* 2010;16:1787-807.
  43. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, et al. Generation of regulatory dendritic cells and CD4<sup>+</sup>FOXP3<sup>+</sup> T cells by probiotics administration suppresses immune disorders. *Proc Natl Acad Sci U S A* 2010;107:2159-64.
  44. Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. *Gut Liver* 2009;3:101-7.
  45. Smith M, Tourigny MR, Noakes P, Thornton CA, Tulic MK, Prescott SL. Children with egg allergy have evidence of reduced neonatal CD4(+)CD25(+)CD127(lo<sup>-</sup>) regulatory T cell function. *J Allergy Clin Immunol* 2008;121:1460-6, 1466.e1-7.
  46. Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. *J Allergy Clin Immunol* 2004;113:756-63.
  47. Taylor AL, Hale J, Hales BJ, Dunstan JA, Thomas WR, Prescott SL. FOXP3 mRNA expression at 6 months of age is higher in infants who develop atopic dermatitis, but is not affected by giving probiotics from birth. *Pediatr Allergy Immunol* 2007;18:10-9.
  48. Wu KG, Li TH, Peng HJ. *Lactobacillus salivarius* plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. *Br J Dermatol* 2012;166:129-36.
  49. Schiavi E, Barletta B, Butteroni C, Corinti S, Boirivant M, Di Felice G. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy. *Allergy* 2011;66:499-508.
  50. Gomez-Llorente C, Munoz S, Gil A. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. *Proc Nutr Soc* 2010;69:381-9.
  51. Finamore A, Roselli M, Britti MS, Merendino N, Mengheri E. *Lactobacillus rhamnosus* GG and *Bifidobacterium animalis* MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats. *J Nutr* 2012;142:375-81.
  52. Ziegler SF. FOXP3: of mice and men. *Annu Rev Immunol* 2006;24:209-26.
  53. Lyons A, O'Mahony D, O'Brien F, MacSharry J, Sheil B, Ccedia M, et al. Bacterial strain-specific induction of Foxp3<sup>+</sup> T regulatory cells is protective in murine allergy models. *Clin Exp Allergy* 2010;40:811-9.
  54. Schiffer C, Lalanne AI, Cassard L, Mancardi DA, Malbec O, Bruhns P, et al. A strain of *Lactobacillus casei* inhibits the effector phase of immune inflammation. *J Immunol* 2011;187:2646-55.
  55. Yoshida A, Yamada K, Yamazaki Y, Sashihara T, Ikegami S, Shimizu M, et al. *Lactobacillus gasseri* OLL2809 and its RNA suppress proliferation of CD4(+) T cells through a MyD88-dependent signalling pathway. *Immunology* 2011;133:442-51.
  56. Rupa P, Schmied J, Wilkie BN. Prophylaxis of experimentally induced ovomucoid allergy in neonatal pigs using *Lactococcus lactis*. *Vet Immunol Immunopathol* 2011;140:23-9.
  57. Kim H, Kwack K, Kim DY, Ji GE. Oral probiotic bacterial administration suppressed allergic responses in an ovalbumin-induced allergy mouse model. *FEMS Immunol Med Microbiol* 2005;45:259-67.
  58. Pochard P, Gosset P, Grangette C, Andre C, Tonnel AB, Pestel J, et al. Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. *J Allergy Clin Immunol* 2002;110:617-23.
  59. Flinterman AE, Knol EF, van Ieperen-van Dijk AG, Timmerman HM, Knulst AC, Bruijnzeel-Koomen CA, et al. Probiotics have a different immunomodulatory potential in vitro versus ex vivo upon oral administration in children with food allergy. *Int Arch Allergy Immunol* 2007;143:237-44.